Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

ICCA-Based ICU Physiological State Space Monitor

14. August 2026 aktualisiert von: Ming Zhong, Shanghai Zhongshan Hospital

Development of an ICU Physiological State Space Monitor Based on the ICCA Database: A Single-Center Retrospective Observational Study

Critically ill patients can deteriorate rapidly across multiple organ systems. Most intensive care unit (ICU) risk tools rely on measurements collected at a single time point and may not fully capture how physiology evolves or how quickly a patient recovers from disturbance. This single-center retrospective observational study will use routinely collected data from the ICCA reporting database at Zhongshan Hospital, Fudan University to develop and internally validate a research prototype called the ICU Physiological State Space Monitor. Adult ICU admissions will be represented as daily state vectors across 10 physiological domains. The study will characterize each patient's position and movement in a multidimensional state space, identify high-risk regions and possible critical transitions, and quantify physiological resilience using trajectory features such as variability, autocorrelation, curvature, recovery slope, and cross-domain coupling. The primary validation outcome is a composite clinical deterioration event within 72 hours after an eligible index patient-day. The monitor is an analytic and visualization framework for retrospective research and will not be deployed for real-time clinical decision-making in this study.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Detaillierte Beschreibung

This is a single-center, retrospective, non-interventional methodological cohort study using routinely collected structured data from the ICCA reporting-layer database at Zhongshan Hospital, Fudan University. The source population comprises adult ICU patients admitted between September 2021 and May 31, 2026 who have an extractable and uniquely identifiable ICU encounter. No intervention will be assigned, no clinical decision will be altered, and no additional examination, treatment, follow-up visit, or biospecimen collection will be performed.

The unit of participant-level registration is the patient, while the principal analytic structure is the ICU encounter and the patient-day. ICU admission time will serve as the common temporal anchor. Monitoring, laboratory, fluid, medication, organ-support, diagnostic, and demographic data will be extracted from the ICCA reporting layer and aggregated primarily into consecutive 24-hour windows. Alternative 12-hour or shorter windows may be evaluated in sensitivity analyses.

Daily physiological state vectors will be constructed across 10 domains: oxygenation; ventilation and respiratory drive; hemodynamic perfusion; renal-fluid balance; hepatic-metabolic clearance; inflammation-immune activation; coagulation-blood integrity; brain-autonomic regulation; bioenergetic and acid-base status; and treatment-support burden. Prespecified data-governance rules will be used for variable-source mapping, unit harmonization, time alignment, limited carry-forward, missing-data handling, and physiological-range checks.

Principal component analysis will provide the primary low-dimensional state-space representation. UMAP may be used for supplementary visualization and local-structure exploration but will not be the sole primary analytical framework. Enhanced trajectory features will include state position, displacement, trajectory length, speed, acceleration, turning angle, curvature, local variability, lag-1 autocorrelation, recovery slope, and cross-domain coupling. These features will be used to characterize high-risk regions, possible basin crossings and critical transitions, and physiological resilience.

Eligible records will be divided chronologically into an earlier derivation cohort and a later temporal validation cohort, with an intended split of approximately 70% and 30%, respectively. The exact cutoff will be locked before analysis. The primary analysis will evaluate the association between state-space and trajectory features and a composite clinical deterioration outcome occurring within 72 hours after each eligible index patient-day. Multivariable logistic regression or discrete-time risk models will be used for the primary outcome. ICU and in-hospital mortality may be evaluated using Cox regression or competing-risk methods, and other outcomes will be analyzed with appropriate regression or time-to-event models. Internal validation will use the temporal validation cohort and bootstrap resampling to assess discrimination, calibration, and robustness.

The source data will remain in the hospital-controlled information environment. Investigators will use a deidentified research dataset without direct identifiers and without access to the reidentification key. Only aggregated results, model parameters, and approved figures will be released. The study seeks a waiver of written informed consent because it is retrospective, non-interventional, uses deidentified existing data, and does not affect participants' current or future care.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

60000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Zhongshan hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Adult patients admitted to an ICU at Zhongshan Hospital, Fudan University between September 2021 and May 31, 2026 who have an extractable, uniquely identifiable ICU encounter in the ICCA reporting-layer database and meet the prespecified eligibility criteria. The study will use a fixed-time-window census of all eligible records. The principal participant count will be based on unique patients; ICU encounters and patient-days will form the analytic units for longitudinal modeling.

Beschreibung

Inclusion Criteria:

  • Age 18 years or older.
  • Admission to an ICU at Zhongshan Hospital, Fudan University between September 2021 and May 31, 2026, with a uniquely identifiable ICU encounter in the ICCA reporting-layer database.
  • ICU length of stay of at least 24 hours.
  • Availability of core variables from at least four physiological domains and at least one patient-day suitable for modeling.

Exclusion Criteria:

  • Duplicate import of the same ICU encounter that cannot be reliably deduplicated.
  • Severe missingness, inconsistency, or irreconcilable error in key identifiers, ICU admission/discharge times, or core timestamps.
  • Test data, demonstration data, or records determined through data governance to be non-genuine patient records.
  • Inability to lock the primary source mapping for key variables, or overall data quality insufficient to support construction of the physiological state vector.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Derivation Cohort
This cohort will be used to construct the physiological state vectors, estimate standardization parameters, develop the low-dimensional state-space representation, characterize trajectory features, and fit the primary prediction/association models.
The exposure of interest is the participant's multidimensional physiological state and trajectory derived from routinely collected ICU monitoring, laboratory, fluid, medication, organ-support, diagnostic, and demographic data. Daily state vectors will cover 10 physiological domains. Enhanced trajectory features will include state position, displacement, trajectory length, speed, acceleration, turning angle, curvature, local variability, lag-1 autocorrelation, recovery slope, and cross-domain coupling. The investigators will not assign any exposure, treatment, or clinical intervention.
Temporal Validation Cohort
This cohort will be held out for temporal internal validation of state-space features, trajectory measures, and associations with prespecified clinical outcomes.
The exposure of interest is the participant's multidimensional physiological state and trajectory derived from routinely collected ICU monitoring, laboratory, fluid, medication, organ-support, diagnostic, and demographic data. Daily state vectors will cover 10 physiological domains. Enhanced trajectory features will include state position, displacement, trajectory length, speed, acceleration, turning angle, curvature, local variability, lag-1 autocorrelation, recovery slope, and cross-domain coupling. The investigators will not assign any exposure, treatment, or clinical intervention.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Composite Clinical Deterioration Within 72 Hours
Zeitfenster: Within 72 hours following each eligible index patient-day
A binary composite outcome defined by the occurrence of at least one of the following events during the 72-hour window after an eligible index patient-day: ICU death; new initiation of invasive mechanical ventilation; new initiation of continuous renal replacement therapy (CRRT); new initiation of extracorporeal membrane oxygenation (ECMO); or a prespecified significant escalation in vasoactive medication support. A participant/index window meeting more than one component will be counted once for the composite outcome.
Within 72 hours following each eligible index patient-day

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
ICU mortality
Zeitfenster: From ICU admission through ICU discharge, an average of approximately 5 days
Death from any cause before discharge from the ICU.
From ICU admission through ICU discharge, an average of approximately 5 days
In-Hospital Mortality
Zeitfenster: From hospital admission through hospital discharge, an average of approximately 30 days
Death from any cause before discharge from the index hospitalization.
From hospital admission through hospital discharge, an average of approximately 30 days
Duration of Invasive Mechanical Ventilation
Zeitfenster: From ICU admission through ICU discharge, an average of approximately 5 days
Total number of calendar days during which invasive mechanical ventilation is used during the ICU stay.
From ICU admission through ICU discharge, an average of approximately 5 days
Duration of Continuous Renal Replacement Therapy
Zeitfenster: From ICU admission through ICU discharge, an average of approximately 5 days
Total number of calendar days during which CRRT is used during the ICU stay.
From ICU admission through ICU discharge, an average of approximately 5 days
Duration of Vasoactive Medication Exposure
Zeitfenster: From ICU admission through ICU discharge, an average of approximately 5 days
Total number of calendar days with recorded vasoactive medication support during the ICU stay.
From ICU admission through ICU discharge, an average of approximately 5 days
ICU Length of Stay
Zeitfenster: From ICU admission through ICU discharge, an average of approximately 5 days
Time from ICU admission to ICU discharge, reported in days.
From ICU admission through ICU discharge, an average of approximately 5 days
Hospital Length of Stay
Zeitfenster: From hospital admission through hospital discharge, an average of approximately 30 days
Time from hospital admission to hospital discharge, reported in days.
From hospital admission through hospital discharge, an average of approximately 30 days

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Estimated 72-Hour Composite Deterioration Risk by Physiological State-Space Location
Zeitfenster: Within 72 hours following each eligible index patient-day
Estimated probability of the 72-hour composite deterioration outcome associated with locations in the low-dimensional physiological state space derived from the prespecified state-space model. The estimated probability will be reported as a percentage ranging from 0% to 100%. High-risk bands, pockets, and local risk landscapes will be considered descriptive features of the estimated risk surface rather than separate outcome measures.
Within 72 hours following each eligible index patient-day
State-Space Displacement Between Consecutive Patient-Days
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Magnitude of change in the participant's position in the PCA-derived low-dimensional physiological state space between two consecutive eligible patient-days, calculated using the prespecified trajectory algorithm and reported in standardized state-space units.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Physiological State-Space Trajectory Length
Zeitfenster: From the first through the last eligible patient-day during the ICU stay, an average of approximately 5 days
Cumulative path length of the participant's trajectory across consecutive positions in the PCA-derived physiological state space, calculated as the accumulated state-space displacement and reported in standardized state-space units.
From the first through the last eligible patient-day during the ICU stay, an average of approximately 5 days
Physiological State-Space Trajectory Speed
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Rate of change in physiological state-space position between consecutive eligible patient-days, calculated from state-space displacement over elapsed time and reported in standardized state-space units per day.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Physiological State-Space Trajectory Acceleration
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Change in physiological state-space trajectory speed between successive eligible patient-day intervals, calculated using the prespecified trajectory algorithm and reported in standardized state-space units per day squared.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Physiological State-Space Turning Angle
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Angular change in trajectory direction between successive trajectory segments derived from consecutive physiological state-space positions, reported in degrees.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Physiological State-Space Trajectory Curvature
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Curvature of the participant's physiological state-space trajectory derived from consecutive state-space positions using the prespecified trajectory algorithm. Higher values indicate greater local directional change in the trajectory.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Local Physiological State-Space Variability
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Within-participant variability in physiological state-space position across consecutive eligible patient-days, calculated using the prespecified trajectory analysis and reported in standardized state-space units. Higher values indicate greater short-term physiological variability.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Lag-1 Autocorrelation of Physiological State-Space Trajectory
Zeitfenster: Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Lag-1 autocorrelation coefficient quantifying the correlation between consecutive physiological state-space observations within the participant's trajectory. The coefficient ranges from -1 to 1, with higher positive values indicating greater persistence of the preceding physiological state.
Across consecutive eligible patient-days from ICU admission through ICU discharge, an average of approximately 5 days
Area Under the Receiver Operating Characteristic Curve for 72-Hour Composite Deterioration
Zeitfenster: Within 72 hours following each eligible index patient-day in the temporal validation cohort
Discrimination of the prespecified state-space and trajectory prediction model in the temporal validation cohort, assessed using the area under the receiver operating characteristic curve (AUROC) for the 72-hour composite deterioration outcome. AUROC ranges from 0 to 1, with higher values indicating better discrimination.
Within 72 hours following each eligible index patient-day in the temporal validation cohort
Calibration Slope for Predicted 72-Hour Composite Deterioration Risk
Zeitfenster: Within 72 hours following each eligible index patient-day in the temporal validation cohort
Calibration of the prespecified state-space and trajectory prediction model in the temporal validation cohort, assessed using the calibration slope comparing predicted probabilities with observed 72-hour composite deterioration outcomes. A calibration slope of 1 indicates ideal calibration.
Within 72 hours following each eligible index patient-day in the temporal validation cohort
Brier Score for Prediction of 72-Hour Composite Deterioration
Zeitfenster: Within 72 hours following each eligible index patient-day in the temporal validation cohort
Overall prediction error of the prespecified state-space and trajectory prediction model in the temporal validation cohort, assessed using the Brier score, calculated as the mean squared difference between predicted probabilities and observed binary 72-hour composite deterioration outcomes. The Brier score ranges from 0 to 1, with lower values indicating better predictive accuracy.
Within 72 hours following each eligible index patient-day in the temporal validation cohort

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Juni 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2027

Studienabschluss (Geschätzt)

31. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

4. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. August 2026

Zuerst gepostet (Tatsächlich)

19. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Deidentified participant-level data will not be made publicly available because the source data are governed by institutional privacy, ethics, and information-security requirements. The data will remain in the hospital-controlled environment. Aggregated results, model parameters, analytic methods, or approved code may be shared where permitted by the ethics committee and institutional data-governance procedures.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren